{"version":"1.0","provider_name":"France Angels","provider_url":"https:\/\/www.franceangels.org\/en\/","author_name":"sylvain Godard","author_url":"https:\/\/www.franceangels.org\/en\/article\/author\/sylvainfranceangels-org\/","title":"Paris Saclay Business Angels soutient Cyberna - France Angels","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"LwAAEbhbe0\"><a href=\"https:\/\/www.franceangels.org\/en\/article\/paris-saclay-business-angels-soutient-cyberna\/\">Paris Saclay Business Angels soutient Cyberna<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.franceangels.org\/en\/article\/paris-saclay-business-angels-soutient-cyberna\/embed\/#?secret=LwAAEbhbe0\" width=\"600\" height=\"338\" title=\"&#8220;Paris Saclay Business Angels soutient Cyberna&#8221; &#8212; France Angels\" data-secret=\"LwAAEbhbe0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(c,d){\"use strict\";var e=!1,o=!1;if(d.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(\/[^a-zA-Z0-9]\/.test(t.secret));else{for(var r,s,a,i=d.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=d.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=new RegExp(\"^https?:$\",\"i\"),l=0;l<n.length;l++)n[l].style.display=\"none\";for(l=0;l<i.length;l++)if(r=i[l],e.source!==r.contentWindow);else{if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if(\"link\"===t.message)if(s=d.createElement(\"a\"),a=d.createElement(\"a\"),s.href=r.getAttribute(\"src\"),a.href=t.value,!o.test(a.protocol));else if(a.host===s.host)if(d.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener(\"message\",c.wp.receiveEmbedMessage,!1),d.addEventListener(\"DOMContentLoaded\",t,!1),c.addEventListener(\"load\",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),a=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),i=d.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/www.franceangels.org\/wp-content\/uploads\/2026\/10\/Visuels-articles-1-1024x505.png","thumbnail_width":1024,"thumbnail_height":505,"description":"Cyberna, startup sp\u00e9cialis\u00e9e dans la d\u00e9tection ultra-pr\u00e9coce des \u00e9tats pr\u00e9canc\u00e9reux, l\u00e8ve des fonds aupr\u00e8s de Paris-Saclay Business Angels (PSBA). L\u2019entreprise d\u00e9veloppe une technologie capable d\u2019identifier, \u00e0 partir d\u2019une simple goutte de sang, des signes mol\u00e9culaires pr\u00e9canc\u00e9reux, avant m\u00eame qu\u2019une tumeur ne se forme.\u00a0 Pour cela, Cyberna combine \u00e9pitranscriptomique, spectrom\u00e9trie de masse et intelligence artificielle. Contrairement&hellip;"}